Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial.
The effect of short-term oral zinc supplementation (zinc sulfate 600 mg/day) on hepatic encephalopathy, was assessed in a double-blind, crossover trial. Fifteen cirrhotic patients with stable, chronic hepatic encephalopathy were randomized to receive either oral zinc or a placebo for 10 days. Following a two-week washout period, these were crossed over to the alternate treatment. Conn's index, which comprises the evaluation of the mental state, asterixis, number connection test, EEG record, and plasma ammonia, was used to score the degree of hepatic encephalopathy, both at the beginning and end of each treatment period. Serum zinc was significantly raised after oral zinc administration and reached the levels observed in cirrhotics without hepatic encephalopathy. Despite this, however, no modification in the parameters included in Conn's index were observed. In conclusion, this study failed to confirm that short-term oral zinc supplementation improves chronic hepatic encephalopathy.
Riggio
O
O
Dipartimento di Chimica, Università di Roma La Sapienza, Italy.
Ariosto
F
F
Merli
M
M
Caschera
M
M
Zullo
A
A
Balducci
G
G
Ziparo
V
V
Pedretti
G
G
Fiaccadori
F
F
Bottari
E
E
D000284:Administration, Oral; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D013431:Sulfates / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D015032:Zinc / Q000008:administration & dosage / Q000627:therapeutic use*; D019287:Zinc Sulfate
D013431:Sulfates; D019287:Zinc Sulfate; D015032:Zinc